The 2018 Rare Neurological Disease Special Report has been published by Neurology Reviews in collaboration with NORD.
Sometimes physical challenges can dictate job and career paths.
True Reply and HNF have collaborated to enhance patient focused research and knowledge of what matters most to patients living with CMT.
StarWise Therapeutics LLC & HNF join forces to expedite the advancement of a new drug entity to the clinic for the treatment of CMT2A.
Though CMT is rarely fatal, respiratory complications are one of the ways it’s possible to die from CMT.
In October 2017, Flex Pharma initiated a Phase 2 study of CMT, referred to as the COMMIT study.
Learn how this CMT1A patient uses the AlterG treadmill to manage her CMT symptoms.
Invitae, A Genetic Information Company, Acquires AltaVoice, HNF’s Global Registry for Inherited Neuropathies (GRIN) Platform Host
Living with CMT can be a challenging journey. Here are some helpful tips.
HNF’s initial gene therapy work will focus on CMT type 6, which is caused by a recessive mutation in the C12orf65 gene and is currently no treatment.
0 Comments